Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Byrd, John C.
Jones, Jeffrey Alan
Furman, Richard R.
Stephens, Deborah Marie
Devereux, Steve
Brown, Jennifer R.
Hillmen, Peter
Hamdy, Ahmed M.
Fardis, Maria
Tawashi, Manal
Wang, Min Hui
Patel, Priti
Mittag, Diana
Krantz, Fanny
Rothbaum, Wayne
Izumi, Raquel
O'Brien, Susan Mary
Wierda, William G.
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] NHS Fdn Trust Denmark Hill, Coll Hosp, London, England
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] St James Univ Hosp, Leeds, W Yorkshire, England
[7] Acerta Pharma, Santa Cruz, CA USA
[8] Pharmacycl Inc, Sunnyvale, CA USA
[9] Acerta Pharma, Redwood City, CA USA
[10] Acerta Pharma, San Carlos, CA USA
[11] Univ Calif Irvine, Irvine, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)
    Pleyer, Christopher
    Cohen, Jeffrey
    Soto, Susan
    Ali, Mir
    Ahn, Inhye E.
    Nierman, Pia
    Valdez, Janet
    Lotter, Jennifer
    Superata, Jeanine
    Tian, Xin
    Wiestner, Adrian
    Sun, Clare
    BLOOD, 2019, 134
  • [42] Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia Beyond Ibrutinib
    Lasica, Masa
    Tam, Constantine S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 761 - 773
  • [43] Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
    Woyach, Jennifer A.
    Stefanovski, Matthew R.
    Goettl, Virginia
    Ruppert, Amy S.
    Smucker, Kelly A.
    Smith, Lisa L.
    Dubovsky, Jason A.
    Towns, William H.
    MacMurray, Jessica
    Davis, Melanie E.
    Mao, Yicheng
    Chang, Betty Y.
    Buggy, Joseph J.
    Byrd, John C.
    Johnson, Amy J.
    BLOOD, 2012, 120 (21)
  • [44] Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy
    George, Binsah
    Chan, Kok Hoe
    Rios, Adan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
    Byrd, J. C.
    Blum, K. A.
    Burger, J. A.
    Coutre, S. E.
    Sharman, J. P.
    Furman, R. R.
    Flinn, I. W.
    Grant, B. W.
    Richards, D. A.
    Zhao, W.
    Heerema, N. A.
    Johnson, A. J.
    Izumi, R.
    Hamdy, A.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia
    Banerji, V
    Aw, A.
    Robinson, S.
    Doucette, S.
    Christofides, A.
    Sehn, L. H.
    CURRENT ONCOLOGY, 2020, 27 (06) : E645 - E655
  • [47] Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma
    Varma, Gaurav
    Johnson, Tyler P.
    Advani, Ranjana H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (07) : 543 - 554
  • [48] Effects of the Bruton's tyrosine kinase inhibitor ibrutinib on humoral immunity in patients with chronic lymphocytic leukemia
    Sun, Clare
    Lee, Yuh Shan
    Lipsky, Andrew
    Farooqui, Mohammed
    Herman, Sarah
    Salem, Dalia
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Aue, Georg
    Wiestner, Adrian
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [49] Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft
    Stavart, Louis
    Halfon, Matthieu
    Dewarrat, Natacha
    Rotman, Samuel
    Golshayan, Dela
    FRONTIERS IN MEDICINE, 2024, 11
  • [50] Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib
    Tam, Constantine S.
    Ou, Ying C.
    Trotman, Judith
    Opat, Stephen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) : 1329 - 1344
12345